Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain

Gertrud Andersen; Per Sjøgren; Steen Honoré Hansen; Niels-Henrik Jensen; Lona Louring Christrup

doi:10.1016/j.ejpain.2003.09.003

Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain

Gertrud Andersen, Per Sjøgren, Steen Honoré Hansen, Niels-Henrik Jensen, Lona Louring Christrup

16 Citations (Scopus)

Abstract

In patients with pain of malignant origin morphine may be administered in high and often increasing doses during extended periods of time. In patients with chronic pain of non-malignant origin morphine may be an important remedy, and in these cases the goal is to keep the morphine dose stable. The pharmacokinetic as well as the pharmacodynamic consequences of long-term morphine treatment with special reference to the two most important metabolites of morphine morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) remain to be settled.

Original language	English
Journal	European Journal of Pain
Volume	8
Issue number	3
Pages (from-to)	263-71
Number of pages	9
ISSN	1090-3801
DOIs	https://doi.org/10.1016/j.ejpain.2003.09.003
Publication status	Published - Jun 2004

Keywords

Adult
Aged
Analgesics, Opioid
Chronic Disease
Dose-Response Relationship, Drug
Drug Administration Routes
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Morphine
Morphine Derivatives
Neoplasms
Pain
Pain Measurement
Salivary Glands
Xerostomia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejpain.2003.09.003

http://www.sciencedirect.com/science/article/pii/S1090380103001265

Cite this

@article{f61bcc5f60f14201bcdfef6f9180d35d,

title = "Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain",

abstract = "In patients with pain of malignant origin morphine may be administered in high and often increasing doses during extended periods of time. In patients with chronic pain of non-malignant origin morphine may be an important remedy, and in these cases the goal is to keep the morphine dose stable. The pharmacokinetic as well as the pharmacodynamic consequences of long-term morphine treatment with special reference to the two most important metabolites of morphine morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) remain to be settled.",

keywords = "Adult, Aged, Analgesics, Opioid, Chronic Disease, Dose-Response Relationship, Drug, Drug Administration Routes, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Morphine, Morphine Derivatives, Neoplasms, Pain, Pain Measurement, Salivary Glands, Xerostomia",

author = "Gertrud Andersen and Per Sj{\o}gren and Hansen, {Steen Honor{\'e}} and Niels-Henrik Jensen and Christrup, {Lona Louring}",

year = "2004",

month = jun,

doi = "10.1016/j.ejpain.2003.09.003",

language = "English",

volume = "8",

pages = "263--71",

journal = "European Journal of Pain",

issn = "1090-3801",

publisher = "JohnWiley & Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain

AU - Andersen, Gertrud

AU - Sjøgren, Per

AU - Hansen, Steen Honoré

AU - Jensen, Niels-Henrik

AU - Christrup, Lona Louring

PY - 2004/6

Y1 - 2004/6

N2 - In patients with pain of malignant origin morphine may be administered in high and often increasing doses during extended periods of time. In patients with chronic pain of non-malignant origin morphine may be an important remedy, and in these cases the goal is to keep the morphine dose stable. The pharmacokinetic as well as the pharmacodynamic consequences of long-term morphine treatment with special reference to the two most important metabolites of morphine morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) remain to be settled.

AB - In patients with pain of malignant origin morphine may be administered in high and often increasing doses during extended periods of time. In patients with chronic pain of non-malignant origin morphine may be an important remedy, and in these cases the goal is to keep the morphine dose stable. The pharmacokinetic as well as the pharmacodynamic consequences of long-term morphine treatment with special reference to the two most important metabolites of morphine morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) remain to be settled.

KW - Adult

KW - Aged

KW - Analgesics, Opioid

KW - Chronic Disease

KW - Dose-Response Relationship, Drug

KW - Drug Administration Routes

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Morphine

KW - Morphine Derivatives

KW - Neoplasms

KW - Pain

KW - Pain Measurement

KW - Salivary Glands

KW - Xerostomia

U2 - 10.1016/j.ejpain.2003.09.003

DO - 10.1016/j.ejpain.2003.09.003

M3 - Journal article

C2 - 15109977

SN - 1090-3801

VL - 8

SP - 263

EP - 271

JO - European Journal of Pain

JF - European Journal of Pain

IS - 3

ER -

Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this